Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.

SIGA Technologies, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, AUG. 05, 2025 (GLOBE NEWSWIRE) -- SIGA TECHNOLOGIES, INC. (SIGA) (NASDAQ: SIGA), A COMMERCIAL-STAGE PHARMACEUTICAL COMPANY, TODAY REPORTED FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025.

SIGA REPORTS FINANCIAL RESULTS FOR THREE AND SIX MONTHS ENDED JUNE 30, 2025

NEW YORK, JULY 29, 2025 (GLOBE NEWSWIRE) -- SIGA TECHNOLOGIES, INC. (SIGA) (NASDAQ: SIGA), A COMMERCIAL-STAGE PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT MANAGEMENT WILL HOST A WEBCAST AND CONFERENCE CALL TO PROVIDE A BUSINESS UPDATE AT 4:30 P.M. ET ON TUESDAY, AUGUST 5, 2025. PARTICIPATING IN THE CALL WILL BE DIEM NGUYEN, CHIEF EXECUTIVE OFFICER, AND DANIEL LUCKSHIRE, CHIEF FINANCIAL OFFICER.

SIGA TO HOST BUSINESS UPDATE CALL ON AUGUST 5, 2025 FOLLOWING RELEASE OF SECOND-QUARTER 2025 RESULTS

RECEIVED $26 MILLION IV TPOXX PROCUREMENT ORDER FROM THE U.S. GOVERNMENT IN MARCH $94 MILLION IN TPOXX ORDERS (TO BE DELIVERED TO U.S. STRATEGIC NATIONAL STOCKPILE) OUTSTANDING AS OF MARCH 31, 2025 CORPORATE UPDATE CONFERENCE CALL TODAY AT 4:30 PM ET NEW YORK, MAY 08, 2025 (GLOBE NEWSWIRE) -- SIGA TECHNOLOGIES, INC. (SIGA) (NASDAQ: SIGA), A COMMERCIAL-STAGE PHARMACEUTICAL COMPANY, TODAY REPORTED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2025. SIGA HAS CARRIED ITS MOMENTUM FROM 2024 INTO 2025, ACHIEVING STEADY PROGRESS ON ITS KEY INITIATIVES, STATED DIEM NGUYEN, CHIEF EXECUTIVE OFFICER.

SIGA REPORTS FINANCIAL RESULTS FOR THREE MONTHS ENDED MARCH 31, 2025

NEW YORK, MAY 01, 2025 (GLOBE NEWSWIRE) -- SIGA TECHNOLOGIES, INC. (SIGA) (NASDAQ: SIGA), A COMMERCIAL-STAGE PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT MANAGEMENT WILL HOST A WEBCAST AND CONFERENCE CALL TO PROVIDE A BUSINESS UPDATE AT 4:30 P.M. ET ON THURSDAY, MAY 8, 2025. PARTICIPATING IN THE CALL WILL BE DIEM NGUYEN, CHIEF EXECUTIVE OFFICER, AND DANIEL LUCKSHIRE, CHIEF FINANCIAL OFFICER.

SIGA TO HOST BUSINESS UPDATE CALL ON MAY 8, 2025 FOLLOWING RELEASE OF FIRST-QUARTER 2025 RESULTS

NEW YORK, APRIL 08, 2025 (GLOBE NEWSWIRE) -- SIGA TECHNOLOGIES, INC. (SIGA) (NASDAQ: SIGA), A COMMERCIAL-STAGE PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS DECLARED A SPECIAL CASH DIVIDEND OF $0.60 PER SHARE ON THE COMPANY'S COMMON STOCK. THIS REPRESENTS THE FOURTH STRAIGHT YEAR OF A SPECIAL CASH DIVIDEND. THE AMOUNT OF THE DIVIDEND DECLARED IS CONSISTENT WITH THE LEVEL OF THE DIVIDEND DECLARED IN MARCH 2024. THE DIVIDEND IS PAYABLE ON MAY 15, 2025, TO SHAREHOLDERS OF RECORD AT THE CLOSE OF BUSINESS ON APRIL 29, 2025.

SIGA DECLARES SPECIAL CASH DIVIDEND OF $0.60 PER SHARE

NEW YORK, MARCH 18, 2025 (GLOBE NEWSWIRE) -- SIGA TECHNOLOGIES, INC. (SIGA) (NASDAQ: SIGA), A COMMERCIAL-STAGE PHARMACEUTICAL COMPANY, ANNOUNCED TODAY THE APPOINTMENT OF RETIRED UNITED STATES ARMY GENERAL JOHN JACK KEANE TO ITS BOARD OF DIRECTORS, EFFECTIVE IMMEDIATELY. GENERAL KEANE, A RETIRED FOUR-STAR GENERAL, COMPLETED 37 YEARS OF PUBLIC SERVICE IN DECEMBER 2003, CULMINATING WITH HIS APPOINTMENT AS ACTING CHIEF OF STAFF AND VICE CHIEF OF STAFF OF THE U.S. ARMY FROM 1999 TO 2003.

SIGA APPOINTS RETIRED GENERAL JOHN M. KEANE TO ITS BOARD OF DIRECTORS

NEW YORK, MARCH 11, 2025 (GLOBE NEWSWIRE) -- SIGA TECHNOLOGIES, INC. (SIGA) (NASDAQ: SIGA), A COMMERCIAL-STAGE PHARMACEUTICAL COMPANY, TODAY REPORTED FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2024.

SIGA REPORTS FINANCIAL RESULTS FOR THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2024

NEW YORK, MARCH 04, 2025 (GLOBE NEWSWIRE) -- SIGA TECHNOLOGIES, INC. (SIGA) (NASDAQ: SIGA), A COMMERCIAL-STAGE PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT MANAGEMENT WILL HOST A WEBCAST AND CONFERENCE CALL TO PROVIDE A BUSINESS UPDATE AT 4:30 P.M. ET ON TUESDAY, MARCH 11, 2025. PARTICIPATING IN THE CALL WILL BE DIEM NGUYEN, CHIEF EXECUTIVE OFFICER, AND DANIEL LUCKSHIRE, CHIEF FINANCIAL OFFICER.

SIGA TO HOST BUSINESS UPDATE CALL ON MARCH 11, 2025 FOLLOWING RELEASE OF FOURTH-QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

NEW YORK, JAN. 02, 2025 (GLOBE NEWSWIRE) -- SIGA TECHNOLOGIES, A COMMERCIAL STAGE PHARMACEUTICAL COMPANY, ANNOUNCED TODAY THAT ITS ANTIVIRAL TREATMENT TEPOXX (TECOVIRIMAT 200 MG CAPSULES), MARKETED AS TPOXX IN THE UNITED STATES, HAS RECEIVED REGULATORY APPROVAL IN JAPAN FOR THE TREATMENT OF SMALLPOX, MPOX, COWPOX, AS WELL AS COMPLICATIONS FOLLOWING SMALLPOX VACCINATION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG. TEPOXX IS THE FIRST ANTIVIRAL THERAPY APPROVED BY THE PHARMACEUTICALS AND MEDICAL DEVICES AGENCY (PMDA), IN COLLABORATION WITH THE JAPAN MINISTRY OF HEALTH, LABOUR AND WELFARE, FOR THE TREATMENT OF ORTHOPOXVIRUSES.

TEPOXX (TECOVIRIMAT) APPROVED IN JAPAN FOR THE TREATMENT OF ORTHOPOXVIRUSES

NEW YORK, DEC. 10, 2024 (GLOBE NEWSWIRE) -- THE NATIONAL INSTITUTES OF HEALTH'S (NIH) NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) TODAY ANNOUNCED RESULTS FROM AN INTERIM ANALYSIS OF THE STUDY OF TECOVIRIMAT FOR HUMAN MPOX VIRUS (STOMP) CLINICAL TRIAL (NCT05534984). NIAID REPORTED THAT SIGA'S TECOVIRIMAT, A HIGHLY TARGETED ANTIVIRAL TREATMENT, DID NOT DEMONSTRATE EFFICACY IN TIME TO SKIN AND MUCOSAL LESION RESOLUTION COMPARED TO PLACEBO IN PATIENTS WITH MILD TO MODERATE CLADE II MPOX. BASED ON THIS AND ADDITIONAL ANALYSES, THE STUDY DATA SAFETY AND MONITORING BOARD (DSMB) RECOMMENDED TO STOP ENROLLING PATIENTS IN THE RANDOMIZED ARMS OF THE STUDY. NIAID ACCEPTED THIS RECOMMENDATION AND SUBSEQUENTLY DECIDED TO TAKE A SIMILAR ACTION IN THE OPEN LABEL ARM OF THIS STUDY, WHICH INCLUDED SEVERE AND AT-RISK OF DEVELOPING SEVERE DISEASE PATIENTS.DATA ANALYSIS IS NOT YET COMPLETE FOR PRIMARY ENDPOINT SUBGROUPS AND DETAILED SECONDARY AND EXPLORATORY ENDPOINTS.

SIGA Technologies, Inc.

SIGA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SIGA Technologies, Inc.

SIGA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SIGA